Clinical trials: psoriasis
Psoriasis Vulgaris
Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris
The purpose of this study is to evaluate the effect of once daily use of LEO 80185 gel on the hypothalamic-pituitary-adrenal (HPA) axis and calcium metabolism in subjects with extensive psoriasis vulgaris.
- Trial name
- NCT01229098
- Testing
- LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
- Where
- 10 sites in Canada
- Volunteers
- 102 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
The objective of this open-label multicentric study is to determine the adrenal suppression potential and the pharmacokinetic (PK) properties of halobetasol lotion (HBP) applied twice daily for up to two weeks in subjects aged 12…
- Trial name
- NCT03212963
- Testing
- Halobetasol Topical Lotion
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Plaque Psoriasis
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
- Trial name
- NCT02749799
- Testing
- DFD-01 (betamethasone dipropionate) Spray, 0.05%
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris
The purpose of the study is to compare the 3 ointment formulations containing LEO 29102 plus calcipotriol and Daivonex® ointment and Diprosone® ointment and to compare LEO 29102 plus calcipotriol to LEO 29102 alone and to…
- Trial name
- NCT01466478
- Testing
- Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment, Ointment B: LEO 29102 2.5 mg/g ointment, Ointment C: Calcipotriol 50 µg/g ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Psoriasis
A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis
Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).
- Trial name
- Left/Right (NCT02180464)
- Testing
- LAS41004, control
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Almirall, S.A.
Chronic Plaque Psoriasis
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic…
- Trial name
- NCT00493324
- Testing
- alefacept, polyvalent pneumococcal vaccine
- Where
- 7 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma Inc
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.
- Trial name
- NCT03669757
- Testing
- LEO 134310, LEO 134310 vehicle, 0.1% betamethasone valerate ointment (class III steroid)
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07474792
- Testing
- ORKA-002
- Where
- 40 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.
- Trial name
- NCT07102888
- Testing
- RSS0393 Ointment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish…
- Trial name
- DANBIO (NCT05421442)
- Where
- United States
- Volunteers
- 38,396 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
- Trial name
- AgAIN (NCT04632927)
- Testing
- Secukinumab, Ustekinumab
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Pilot observational study to describe the relationship between the smoking status of a psoriatic individual and the success of etanercept therapy in psoriasis treatment
- Trial name
- NCT02192164
- Testing
- smoking questionnaire
- Where
- 8 sites in Hungary
- Volunteers
- 126 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
- Trial name
- CIMREAL (NCT04053881)
- Testing
- Certolizumab pegol
- Where
- 79 sites in Belgium, Canada and 7 more
- Volunteers
- 412 people
- Sponsor
- UCB Biopharma SRL
Moderate to Severe Chronic Plaque-type Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03504852
- Testing
- secukinumab 150 mg
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 331 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis
GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma) that is under development for topical treatment of plaque type psoriasis suitable for topical…
- Trial name
- NCT02548052
- Testing
- GSK2981278 0.03%, GSK2981278 0.1%, GSK2981278 0.8%
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Psoriasis
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
This study will evaluate the efficacy and safety of GSK2894512 cream for the topical treatment of plaque psoriasis (psoriasis) with its vehicle cream.
- Trial name
- NCT03202004
- Testing
- GSK2894512 1% cream, Vehicle cream
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.